StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
MYGNBearishLegalnews
High materiality7/10

Myriad Genetics faces 2026 guidance cut and investor investigation

Aug 4, 2026, 10:10 AM EDT3 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Combination of a downward revision to revenue, suspended EBITDA guidance, and an active securities investigation tends to weigh on equity sentiment and could drive near-term selling pressure until clarity improves.

AI summary

What happened, with direct paths to the underlying reporting

Myriad Genetics reduced 2026 revenue guidance to 770-790 million while keeping gross margin at 68-69% and suspending EBITDA guidance. A third-party firm, SueWallSt, launched a securities investigation questioning whether cost and reimbursement pressures were adequately disclosed before the revision, adding legal risk alongside weaker top-line dynamics. The combination could weigh on sentiment and near-term stock performance unless guidance or resolution improves.

  • MYGN guided 2026 gross margin to 68-69%; revenue outlook cut by about $90M.
  • Adjusted EBITDA guidance suspended; reimbursement pressure cited as a key driver.
  • SueWallSt launches shareholder investigation into MYGN disclosures on cost/reimbursement.
  • May 5, 2026 CFO reaffirmed guidance; investigation questions disclosure adequacy around revisions.
  • Investors urged to review losses; no upfront costs to participate.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event